Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5967334 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL5966841 | 0.91 | ALDH1A1 (0.49) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL5966897 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL5967356 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL20515051 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL5966948 | 0.87 | CYP2C9 (0.49) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL7365506 | 0.87 | ALDH1A1 (0.48) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL7366464 | 0.86 | PSEN1 (0.43) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL5967171 | 0.85 | CYP2C9 (0.50) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 | |
| SCHEMBL5966981 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2HTTL3MBTL1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888022-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ATHENA NEUROSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | SMN1; SMN2 1690/4885HTT 50/4885L3MBTL1 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.